- Home
- ANAB vs REPX Comparison
ANAB vs REPX Comparison
Compare ANAB & REPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- REPX
- Stock Information
- Founded
- ANAB 2005
- REPX 2016
- Country
- ANAB United States
- REPX United States
- Employees
- ANAB N/A
- REPX N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- REPX Oil & Gas Production
- Sector
- ANAB Health Care
- REPX Energy
- Exchange
- ANAB Nasdaq
- REPX Nasdaq
- Market Cap
- ANAB 621.1M
- REPX 574.1M
- IPO Year
- ANAB 2017
- REPX N/A
- Fundamental
- Price
- ANAB $23.17
- REPX $27.88
- Analyst Decision
- ANAB Buy
- REPX Strong Buy
- Analyst Count
- ANAB 10
- REPX 1
- Target Price
- ANAB $44.25
- REPX $47.00
- AVG Volume (30 Days)
- ANAB 775.6K
- REPX 98.8K
- Earning Date
- ANAB 08-04-2025
- REPX 08-06-2025
- Dividend Yield
- ANAB N/A
- REPX 5.42%
- EPS Growth
- ANAB N/A
- REPX N/A
- EPS
- ANAB N/A
- REPX 4.67
- Revenue
- ANAB $111,872,000.00
- REPX $412,894,000.00
- Revenue This Year
- ANAB N/A
- REPX $2.85
- Revenue Next Year
- ANAB $24.39
- REPX $4.05
- P/E Ratio
- ANAB N/A
- REPX $6.00
- Revenue Growth
- ANAB 387.20
- REPX 1.25
- 52 Week Low
- ANAB $12.21
- REPX $21.98
- 52 Week High
- ANAB $41.31
- REPX $37.55
- Technical
- Relative Strength Index (RSI)
- ANAB 56.01
- REPX 55.00
- Support Level
- ANAB $22.46
- REPX $27.67
- Resistance Level
- ANAB $24.17
- REPX $28.94
- Average True Range (ATR)
- ANAB 1.72
- REPX 0.99
- MACD
- ANAB -0.01
- REPX 0.09
- Stochastic Oscillator
- ANAB 73.23
- REPX 63.64
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties and Tennessee Properties, among others.